期刊文献+

肿瘤细胞中药物代谢酶表达和活性的研究与进展 被引量:6

A review of the expression and activity of drug metabolism enzymes in tumorous cells
原文传递
导出
摘要 肿瘤细胞具有十分独特的生存与代谢模式,研究肿瘤细胞的药物代谢特征对于了解药物在肿瘤细胞中的代谢和消除快慢进而评估并预测药效、基于代谢特征优化抗肿瘤药物/前体药物设计具有重要意义。本文综述了肝、肠、乳腺和肺等常见癌组织的主要药物代谢相关酶的表达/活性及其与正常组织的差异,阐述了部分典型抗肿瘤药物在肿瘤组织中的代谢特征,结合对应的常用体外培养肿瘤细胞株中药物代谢酶的表达/活性特征,探讨实体肿瘤组织(体内)和肿瘤细胞株(体外)中酶表达与功能的异同性及差异的产生原因。 Tumorous cells are characterized by distinctive metabolic reprogramming and living conditions. Understanding drug metabolizing features in tumor cells will not only favor the estimation of metabolic rate, elimination half life and the assessment of potency, but also facilitate the optimal design of anti-tumor drugs/prodrugs. This article reviewed the expression and activity features of major drug metabolizing enzymes (DMEs) in solid tumorous tissues, such as liver, intestine, breast and lung, and the difference from the correspondingly normal tissues, exemplified by the metabolic properties of some classic antitumor-agents in tumorous tissues. In combination with the data retrieved in vitro tumor cell lines, we discussed the similarities and differences of DMEs expression and function between tumor tissues (in vivo) and tumor cells (in vitro), and proposed the possible factors that cause the differences.
出处 《药学学报》 CAS CSCD 北大核心 2014年第10期1377-1386,共10页 Acta Pharmaceutica Sinica
基金 江苏省自然科学基金资助项目(BK2012762)
关键词 肿瘤组织/细胞 体外培养细胞株 药物代谢酶 药物设计 tumor tissue/ceil in vitro cell line drug metabolizing enzyme drug design
  • 相关文献

参考文献3

二级参考文献41

  • 1余堂宏,贾汝汉,丁国华,熊燕,陈健.霉酚酸酯对2型糖尿病大鼠肾脏的保护作用[J].中国临床药理学与治疗学,2004,9(10):1119-1122. 被引量:7
  • 2Kalthoff S, Ehmer U. Interaction between oxidative stress sensor Nrf2 and xenobiotie-aetivated aryl hy- drocarbon receptor in the regulation of the human phase Ⅱ detoxifying UDP-glueuronosyltransferase 1A10[J]. JBiolChem, 2010, 285(9) :5993-6002.
  • 3Tukey RH, Strassburg CP. Human UDP-glucuro nosyltransferases: metabolism, expression, and disease[J]. Annu Rev Pharmacol Toxicol, 2000, 40:581-616.
  • 4Cummings J, Ethell BT. Glucuronidation as a mechanism of intrinsic drug resistance in human co- lon cancer: reversal of resistance by food additives [J]. Cancer Res, 2003,63(23):8443-8450.
  • 5Gregory PA, Gardner Stephen DA, Lewinsky RH, et al. Cloning and characterization of the human UDP-glueuronosyltransferase 1A8, 1A9, and 1AIO gene promoters: differential regulation through an interior-like region[J]. J Biol Chem, 2003, 278 (38) :36107-36114.
  • 6Barbier O, Girard H, Inoue Y,et al. Hepatic ex- pression of the UGTIA9 gene is governed by hepa tocyte nuclear factor 4alpha[J]. Mol Pharmacol, 2005,67(1) :241-249.
  • 7Carlini LE, Meropol NJ, Bever J,et al. UGTIA7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan[J]. Clin Cancer Res, 2005, 11 (3) : 1226- 1236.
  • 8Cecchin E, Innocenti F, D'Andrea M,et al. Predic- tive role of the UGTIAI, UGTIA7, and UGTIA9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouraeil, leucovorin, and irinotecan[J]. J Clin Oncol, 2009 , 27(15):2457 -2465.
  • 9Inoue K, Sonobe M, Kawamura Y, et al. Polymor- phisms of the UDP-Glucuronosyl Transferase la genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy [J]. TohokuJ Exp Med, 2013,229(2) :107-114.
  • 10A1 Saabi A, Allorge D, Sauvage FL, et al. Involve- ment of UGTIA9 and UGT2B7 in ethanol glucu ronidation, and interactions with common drugs of abuse[J]. Drug Metab Dispos,2013 ,41(3) :568- 574.

共引文献9

同被引文献30

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部